Experience Abbott at AACC On-Demand

Now through January 18, 2021



AACC may look different this year, but our goals remain the same.
Our virtual booth will bring you new ways to achieve measurably better healthcare performance with our personalized solutions consisting of Resourceful Advocates, Harmonized Systems and Intelligent Insights.

Resourceful Advocates Icon
Resourceful Advocates


Harmonized Systems Icon
Harmonized SystemS

Alinity Intelligent Insights Icon
Intelligent Insights

Its time to future-proof your lab for the evolving healthcare environment.


core diagnostics solutions

Experience leading-edge technology with demonstrations of our innovative systems, automation and informatics.

Alinity Systems

Learn More


* The Alinity h-series is available in select countries, not including the United States.



Learn More


AlinIQ Informatics &
Professional Services

Learn More





Keynote Address



The Future of Lab Medicine:
Driving Health Through Innovation, Quality and Sustainability

Join us for an exciting presentation from Divisional Vice President, Vahe Ayvazian. He will share how Abbott can help your laboratory lead the future of healthcare through five opportunities for better outcomes in the COVID-19 era and beyond.

More To Explore



The UNIVANTS of Healthcare Excellence program is a prestigious global award program with a common vision to inspire and celebrate healthcare excellence. At AACC, learn how 2020 award winners are bringing measurably better healthcare to life as they share details on their best practices.

Learn More



Change and risk are the new normal in healthcare due to staffing shortages, reimbursement cuts and more. With the Abbott Transformation System, we partner with you to create a strategic plan to realize clinical, operational and financial efficiency. During the virtual show, visit the Abbott Transformation System area to learn how you can create impact in and beyond your lab.

Scientific Exchange


Scientific Presentations 


View panel discussions and moderated sessions featuring key opinion leaders and Abbott experts that you won't find anywhere else.


What We Have Learned


Part 1: A quick outlook on COVID-19 disease, pathogenetic mechanisms and the diagnostic and prognostic parameters.

Part 2: In a panel discussion format, this session will provide a comprehensive view of the available diagnostic solutions for SARS-CoV-2 infection, starting with high-sensitive and robust nucleic acid amplification methods and spanning to rapid RNA or antigen detection methods and the variety of solutions aimed to detect the host immune response. The different solutions will be described both in the context of diagnosis and of recovery and surveillance. 

Claudio Galli MD, PhD
- Moderator - 

Global Associate Medical Director for Infectious Diseases, Abbott
Rome, Italy

Luis M.F. Gonzalez, MD, PhD
Global Senior Director of Medical and Scientific Affairs, Rapid Diagnostics, Abbott
Lake Forest, Illinois

David Daghfal, MS MBA
Scientific Affairs Manager,
Diagnostics, Abbott
Lake Forest, Illinois

Norman Moore, PhD
Volwiler Senior Associate Research Fellow, Director Infectious Diseases, Scientific Affairs,
Rapid Diagnostics, Abbott
Scarborough, Maine

Alexander Carterson, MD, PhD
Global Medical Director,
Transfusion Medicine, Abbott
Lake Forest, Illinois

When One Pandemic Overshadows Another, Ignorance Becomes Bliss: Effects of COVID-19 on Drug Abuse Trends & Deaths

In the throes of the COVID-19 pandemic, the drug abuse pandemic is barely mentioned in mainstream media. However, data demonstrate that the viral epidemic has led to a surge in the drug pandemic. These data will be reviewed from a laboratory perspective followed by a discussion of reasons for this phenomenon. How drug cartels have responded to interruptions in supplies and vectors for distribution will also be discussed as well as what holds for the future as the battle of pandemics rages on.

Randy Schneider, PhD, FAACC
- Moderator -

Scientific Affairs Manager, Diagnostics, Abbott
Lake Forest, Illinois

Robert A. Middleberg, PhD, DABCC(TC), F-ABFT
Laboratory Director and Senior VP of QA and Regulatory Affairs,
NMS Labs
Horsham, Pennsylvania


Longitudinal Characterization of the IgM and IgG Humoral Response in Symptomatic COVID-19 Patients Using Abbott ARCHITECT

This session will review a recent study conducted at Royal Oak Hospital in Beaumont, Michigan that demonstrates the validation of the usage of ARCHITECT SARS-CoV-2 IgG and IgM serology assays in their laboratory. The study goes on to characterize the humoral response in COVID-19 hospitalized patients utilizing the same Abbott ARCHITECT assays. This evaluation highlights some of the key benefits of using serology in the characterization, treatment and monitoring/management of COVID-19 disease during the pandemic.    

David Daghfal, MS MBA
- Moderator - 
Scientific Affairs Manager, Diagnostics, Abbott 

Lake Forest, Illinois

Dr. Qian Sun PhD. DABCC
Technical Director of Chemistry Lab, Associate Professor of Pathology,
Royal Oak Hospital
Beaumont, Michigan





Join expert clinicians for a virtual roundtable discussion of traumatic brain injury. During this session, the breadth of this problem, patient presentation, clinician assessment and potential advancements in objective brain assessment will all be discussed. In addition, rule based medicine and advancements in concussion assessment will be reviewed in detail. Recent research utilizing blood testing to help clinicians evaluate the brain will be highlighted.

Beth McQuiston MD
- Moderator -

Medical Director, Diagnostics, Abbott
Lake Forest, Illinois

Robert D. Welch, MD MS
Professor, Clinical Educator, Department of Emergency Medicine and Director of the Biostatics and Epidemiology
Research Design Group
Detroit, Michigan

Jeff Bazarian, MD, MPH
Professor of Emergency Medicine, Neurology, Neurosurgery, and PHS, University of Rochester, Emergency Medicine Research
Rochester, New York


Part 1: The Clinical value of high-sensitivity Toponin I in cardiovascular risk prediction of the asymptomatic population.*

Part 2: How cardiac biomarkers can improve the cardiovascular risk prediction experts panel discussion.


Christos Varounis, MD, MSc, MBA
- Moderator -
Cardiologist, Associate Medical Director, Diagnostics, Abbott
Lake Forest, Illinois

Christie Mitchell Ballantyne, MD
Professor, Baylor College of Medicine,
Houston, Texas

Nicholas Mills 
Chair of Cardiology, Butler BHF Senior Clinical Research Fellow and Consultant Cardiologist, The University of Edinburgh
Edinburgh, Scotland

*High Sensitive Troponin I risk stratification claim is available in CE Mark and select registered countries, not currently available in the United States





View Abbott's scientific posters and hear from their authors within the aacc virtual event. Preview poster topics below.


Title First Author
Performance Evaluation of the Abbott ARCHITECT and Alinity i Thyroglobulin (Tg) Chemiluminescent Microparticle Immunoassay M.L. Bhandari
Method Comparison of Seven TDM Drugs Across Three Abbott Diagnostics Platforms: ARCHITECT c, ARCHITECT i, and Alinity c V. Higgins
High Sensitivity Troponin I Characterization on Alinity vs ARCHITECT at Two Unique Sites R. Inzitari
Time-related Performance Characteristics of High Sensitivity Troponin I Controls and Reagents D. Daghfal
Performance Evaluation of Abbott SARS-CoV-2 IgG and IgM Assays L. VanHorn
Repeated Hypoglycemic Episodes in a Patient with Type 1 Diabetes: Considerations in Insulin Measurement D. Wang
Evaluation and Implementation of a High Sensitivity Troponin I Assay (Beaumont) S. Truscott
Evaluation of Abbott Fertility and Pregnancy Assay Lot-to-Lot Variability  K. Johnson
Dramatic Decreases in Unnecessary Repeat QC and Calibrations Through Application of Six Sigma to High Volume Lab Tests K. Sobhani
Assessment of the Performance of Clinical Chemistry Assays on the Abbott Alinity and ARCHITECT Platforms Using the New CLIA Proposed Rules for Acceptance Limits for Proficiency Testing W. Stevens
Performance of Selected Hepatitis/ HIV Immunoassays on the Alinity i Analyzer, Abbott’s Next Generation Immunochemistry System D. Lindenblatt 
 Analytical Performance Assessment of an Automated Research Use Only immunoassay for Abbott’s Alinity i and ARCHITECT i systems  M. Datwyler
 Performance Evaluation of Representative Clinical Chemistry Assays for C-reactive protein (CRP) on the Alinity c Analyzer from Abbott Laboratories  J. Lee
 Analytical Performance Assessment of a Newly Formulated REACH compliant Amylase Assay for Abbott’s Alinity c and ARCHITECT c Systems  J. Rhinehart
 Performance of Alinity i AFP Assay        K. Grasso
 Performance of Hepatitis and Retrovirus Infectious Disease Assays on the Alinity i Analyzer  K. Grasso
Alinity i ROMA Assay: A Precise Fully Automated Method for the Assessment of Ovarian Adnexal Mass  N. Benina
ARCHITECT / Alinity SARS-CoV-2 IgG and IgM Assays: A Precise Fully Automated Method for the Qualitative Detection of Human Antibodies to SARS-CoV-2 J. Prostko
Alinity hq PLT Counts: A Comparison with Two Platforms and Four Methods for Measuring PLT Concentrations  G. Lakos
 Comparative Evaluation of the Alinity hq Hematology Analyzer on an Onco-hematology Patient Population  Z. Mukhtar
 Multi-platform Comparison of the Alinity hq Hematology Analyzer    Z. Mukhtar
 Critical Role of Hematology Laboratory Parameters in Severe COVID 19 Infection: A Case Report from Orbassano, Italy F. Crema 
 Comparison of Alinity hq with Sysmex XN-3000 Suggests Equivalent Analytical Performance   Z. Mukhtar


Check back frequently for more information. Presentations and demonstrations will be available on-demand following AACC.




Learning Guides

Build key laboratory competencies and explore topics from various disciplines with our learning guides.

Visit the Learning guides


Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Visit Knowledge Center  


Webinar: Total Value of Ownership

Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach. 

Watch The Webinar 

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No


Content is not under the control of corelaboratory.abbott.

Yes No